DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins

Recruiting now

Conditions studied: Neurofibromas, MPNST

In brief

The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.

Key facts

Study ID

NCT07298083

Run by

M.D. Anderson Cancer Center

People needed

60

Starts

2026-04-02

Expected to finish

2032-04-20

Last updated by the study team

2026-04-09

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• This study will enroll approximately 60 participants diagnosed with either MPNST or neurofibroma who are undergoing surgical resection of an MPNST or neurofibroma as part of their standard of care.
• Age ≥ 1 years. Individuals younger than 18 years old will be included. For patients of age < 18 years, both parents' signatures will be requested.
• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.
• Recurrent or primary disease.
• Patients who are > 18 years should have the ability to understand and the willingness to sign a written informed consent document.
• English and non-English speaking patients.

You may not qualify if…

• Adult patients with cognitive impairment requiring a legally authorized representative for consent.
• Patients under age 1 and neonates.
• Patients who are pregnant and undergoing surgery for MPNST are not eligible.

Where it is running

• The University of Texas M. D. Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.